<SEC-DOCUMENT>0001104659-25-013936.txt : 20250214
<SEC-HEADER>0001104659-25-013936.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214143740
ACCESSION NUMBER:		0001104659-25-013936
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Esperion Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001434868
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87536
		FILM NUMBER:		25626959

	BUSINESS ADDRESS:	
		STREET 1:		3891 RANCHERO DRIVE, SUITE 150
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-887-3903

	MAIL ADDRESS:	
		STREET 1:		3891 RANCHERO DRIVE, SUITE 150
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HDL THERAPEUTICS INC
		DATE OF NAME CHANGE:	20080513

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BB BIOTECH AG
		CENTRAL INDEX KEY:			0000924223
		STANDARD INDUSTRIAL CLASSIFICATION:	UNKNOWN SIC - 0000 [0000]
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		SCHWERTSTRASSE 6
		CITY:			SCHAFFHAUSEN
		STATE:			V8
		ZIP:			8200
		BUSINESS PHONE:		411724 59 59

	MAIL ADDRESS:	
		STREET 1:		SCHWERTSTRASSE 6
		CITY:			SCHAFFHAUSEN
		STATE:			V8
		ZIP:			8200
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001193125-16-721586</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: BB BIOTECH AG -->
          <cik>0000924223</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>12</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001434868</issuerCik>
        <issuerName>Esperion Therapeutics, Inc.</issuerName>
        <issuerCusip>29664W105</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>3891 Ranchero Drive, Suite 150</com:street1>
          <com:city>Ann Arbor</com:city>
          <com:stateOrCountry>MI</com:stateOrCountry>
          <com:zipCode>48108</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>BB Biotech AG</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>V8</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>9944064.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>9944064.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>9944064.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.0</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Biotech Target N.V.</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>P8</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>9944064.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>9944064.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>9944064.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.0</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Esperion Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>3891 Ranchero Drive Suite 150 Ann Arbor, MI, 48108</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Target N.V. ("Biotech Target")</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>BB Biotech: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland
Biotech Target: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curacao</principalBusinessOfficeOrResidenceAddress>
        <citizenship>BB Biotech: Switzerland
Biotech Target: Curacao</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>9,944,064</amountBeneficiallyOwned>
        <classPercent>5.0%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>9,944,064</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>9,944,064</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>This statement is filed jointly by BB Biotech and Biotech Target. Biotech Target is a wholly-owned subsidiary of BB Biotech.</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.*
*Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.'s Schedule 13G filed with the Securities and Exchange Commission on September 27, 2016.</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>BB Biotech AG</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Martin Gubler</signature>
        <title>Martin Gubler/Signatory Authority</title>
        <date>02/12/2025</date>
      </signatureDetails>
      <signatureDetails>
        <signature>/s/ Ivo Betschart</signature>
        <title>Ivo Betschart/Signatory Authority</title>
        <date>02/12/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Biotech Target N.V.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Jan Bootsma</signature>
        <title>Jan Bootsma/Signatory Authority</title>
        <date>02/12/2025</date>
      </signatureDetails>
      <signatureDetails>
        <signature>/s/ Hugo von Neutegem</signature>
        <title>Hugo von Neutegem/Signatory Authority</title>
        <date>02/12/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
